Status:
COMPLETED
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
Eligibility Criteria
Inclusion
- Ocular hypertension or primary open-angle glaucoma in each eye
- Patient requires IOP lowering medication in each eye
Exclusion
- Ocular hyperemia or other ocular surface findings in either eye
- Active ocular disease
- Current or anticipated use of any topical ocular medication (including artificial tears) during the study
- Intraocular surgery within past six months or unilateral cataract surgery.
- Functionally significant visual field loss
- Anticipated wearing of contact lenses during study
- Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT01001195
Start Date
November 1 2009
End Date
April 1 2010
Last Update
October 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rochester, New York, United States